SecBot SecBot
8-K ·Filed Nov 4, 2026

VCYT

VERACYTE, INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed12d 6h ago SEC0001384101-26-000053
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor Decipher Prostate volume trends and the impact of Convergent Genomics acquisition on bladder cancer testing revenue. The narrowed guidance and flat non-GAAP EPS YoY suggest limited near-term upside catalysts despite the buyback authorization.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$24.00
T+0 close · Nov 4, 2026 · via day close
Latest settled
+2.63%
T+5 · $24.63 · next T+20 in 17d
Vs SPY
−0.67%
α at T+5
Latest observation
−0.82%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $24.00entry
  2. T+1 · 11d ago +0.67%α +0.35% · $24.16
  3. T+5 · 5d ago +2.63%α −0.67% · $24.63
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Veracyte reported Q3 2026 revenue of $151.8M (+15% YoY), slightly above the $147.2M consensus, and GAAP EPS of $0.38, below the $0.41 Street estimate. The company narrowed its full-year revenue guidance to $590M-$593M from $590M-$596M, reflecting a modest trim to the top end. A $100M share repurchase program was announced. Decipher Prostate volume was below expectations, while Afirma outperformed.

Key Financial Metrics

EPS
$0.38
est $0.41 · -7.3%
Revenue
$151.8M
est $147.2M · +3.1% · +15.1% YoY
Rating
in line
Guidance
$590M-$593M
maintained
Gross Margin
70.6%

Key Facts

  • Q3 2026 total revenue $151.8M, +15% YoY vs $131.9M; consensus was $147.2M
  • GAAP diluted EPS $0.38 vs $0.24 YoY; consensus was $0.41
  • Non-GAAP diluted EPS $0.51, flat YoY
  • Testing revenue $146.4M, +15% YoY; Decipher Prostate +12% to $92.3M, Afirma +19% to $51.5M
  • Full-year 2026 revenue guidance narrowed to $590M-$593M from $590M-$596M; testing revenue guidance trimmed to $571M-$573M from $576M-$582M
  • Adjusted EBITDA margin guidance unchanged at >26%
  • Board authorized $100M share repurchase program, expiring in 12 months
  • Acquired Convergent Genomics, Inc. to expand urology portfolio
  • Secured Medicare reimbursement for Prosigna Breast ROR test in the U.S.
  • Cash, cash equivalents and short-term investments $370.5M as of Sep 30, 2026

Financial Impact

Revenue beat consensus by ~3.1%; GAAP EPS missed by ~7.3%; guidance narrowed slightly; $100M buyback authorized (2.6% of $3.9B market cap)

revenueepsguidanceshare repurchase

Segment Breakdown

SegmentRevenueGrowth
Testing revenue$146.4M+14.6%
Product revenue$4.6M+40.1%
Biopharmaceutical and other revenue$709.0K-13.0%

Risk Factors

  • Decipher Prostate volume below expectations may signal competitive or reimbursement headwinds
  • Full-year revenue guidance trimmed at the top end, indicating slower H2 momentum
  • Non-GAAP EPS flat YoY despite revenue growth, suggesting margin pressure from higher operating expenses

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
84% bullish (19 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001384101-26-000053
Document: vcyt-20261104.htm0001384101-26-000053
Document: 0001384101-26-000053-index-headers.html0001384101-26-000053
Document: 0001384101-26-000053-index.html0001384101-26-000053
Document: 0001384101-26-000053.txt0001384101-26-000053
8-K Data (Synthetic)0001384101-26-000053

Track record

22 reports on VCYT

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.37% at T+20 after the Jun 11, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $24.63 Now $24.01 −2.52% settles Dec 11
  2. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $24.00 Now $24.01 +0.04% settles Dec 4
  3. Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $24.00 Now $24.01 +0.04% settles Dec 4
  4. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $50.01 Now $24.01 −51.99% settles Nov 30
  5. Oct 28, 202619d ago Insider Cluster Neutral 2/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
  6. Oct 28, 202619d ago Insider Cluster Neutral 3/10 Entry $52.17 Now $24.01 −53.98% settles Nov 27
  7. Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
  8. Oct 27, 202620d ago 144 Neutral 2/10 Entry $50.31 Now $24.01 −52.28% settles Nov 25
  9. Sep 22, 20267w ago Insider Cluster Neutral 2/10 Entry $43.82 to $46.22 Now $24.01 −45.21% ▲ +5.48% +4.79% vs SPY
  10. Sep 14, 20269w ago Press Release Bullish 6/10 Entry $40.14 to $43.11 Now $24.01 −40.18% ▲ +7.40% +4.68% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (10h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026